Android app Apple app link

AstraZeneca pays up to $1bn for biotech firm 'that could transform cell therapy'

By The Guardian   |   1 day ago
AstraZeneca pays up to $1bn for biotech firm 'that could transform cell therapy'

AstraZeneca acquires Belgian biotech firm EsoBiotec for $1bn, expanding its cancer immunotherapy portfolio. The EU approves Imfinzi lung cancer drug, with positive results for rare disease treatment. AstraZeneca continues to grow through strategic acquisitions and partnerships.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.